SBTX News and Press, Silverback Therapeutics Inc. From 05/13/21

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

SBT6290 Shown to Activate Myeloid Cells and Drive Anti-tumor Effects in Nectin4-expressing Solid Tumors Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platf...

Silverback Therapeutics (SBTX): Q4 GAAP EPS of -$1.37 misses by $0.79.Cash and cash equivalents of $386.6M.Press Release For further details see: Silverback Therapeutics EPS misses by $0.79

Initiated SBT6050 clinical development, with pharmacological activity demonstrated in the first dose cohort Advanced preclinical development of SBT6290 and declared SBT8230 as the development candidate for chronic hepatitis B virus program Raised $441.2 million includi...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

The following slide deck was published by Silverback Therapeutics, Inc. in conjunction with this event. For further details see: Silverback Therapeutics (SBTX) Investor Presentation - Slideshow

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

After a monumental year for biopharma investment in 2020, how much of that momentum can the sector carry over into the new year? Market watchers are beginning to place their bets. This year, the annual Biotech Showcase event went digital in the face of the global COVID-19 pandemic, ...

As the post-IPO quiet period ends for Silverback Therapeutics (SBTX), Goldman Sachs weighs in on the stock with a buy recommendation, citing the company’s unique platform targeting the immune system.The price target is $43, implying only ~14.2% upside on today’s close after the ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...